Patent · US Active

Solid forms

US12134599B2 · kind B2 · utility

0Cited by

2References

20Claims

0Family size

Assignees

River 3 Renal Corp. · US
Hoffmann-La Roche Inc. · US

Inventors

He Hongyan · Shanghai, CN
Jiang Siyi · Shanghai, CN
Urs Schwitter · Reinach, CH
Pascal Dott
Ralph Diodone · Breisach am Rhein, DE
Nicole Wyttenbach · Little Falls, US
Olaf Grassmann · Soest, DE

Key dates

Filing date	Oct 11, 2023
Grant date	Nov 5, 2024
Priority date	—
Expiry date	Oct 11, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.